Category Archives: Cell Biology

Research Roundup: Different Antibody Responses to COVID-19 and More – BioSpace

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Antibodies Respond Differently to Severe Versus Mild COVID-19

Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. In addition, they fade differently based on the severity of the case. People with severe COVID-19 have low proportions of antibodies that target the spike protein. In milder cases, the antibodies seem to do a better job of binding to the spike protein. The spike protein binds to the ACE2 receptor on human cells, which allows the virus to enter the cell. Once inside, the virus gets rid of its outer coat, takes over the cells protein-making machinery and churns out more viral particles that then infect other cells. Antibodies that bind to the spike protein block the ability to bind to ACE2. Antibodies that bind to other parts of the virus dont seem to prevent viral spread.

Antibody responses are not likely to be the sole determinant of someones outcome, said Scott Boyd, associate professor of pathology at Stanford. Among people with severe disease, some die and some recover. Some of these patients mount a vigorous immune response, and others have a more moderate response. So, there are a lot of other things going on. There are also other branches of the immune system involved. Its important to note that our results identify correlations but dont prove causation.

Understanding Brain Plasticity in Adults

When brains develop, they constantly grow new neuronal connectionssynapsesas they learn and remember. Important connects are nurtured and reinforced while seemingly unnecessary ones are pruned. Adult brains undergo similar treatment, but its not well understood why adult synapses are eliminated. A group of researchers at The Korean Advanced Institute of Science and Technology (KAIST) have found the underlying mechanism of plasticity, which could be related to neurological disorders in adult brains. The brains gray matter contains microglia and astrocytes. Microglia are a frontline immune defensethey eat pathogens and dead cells. Astrocytes are star-shaped cells that help structure the brain and maintain homeostasis with involvement in neuronal signaling. It was long thought that microglial eat synapses as part of their clean-up effort, a process called phagocytosis. But their research, using a new molecular sensor, found that it was actually the astrocytes that are constantly eliminating excessive and unnecessary adult excitatory synaptic connections.

New Class of Antibiotic Works Against Range of Bacteria

Investigators withThe Wistar Institute have identified a new class of antibiotics that have a broad range of antibacterial effects, including against microbes with antimicrobial resistance (AMR). They focused on a metabolic pathway essential for bacteria but absent in humans, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, which is responsible for biosynthesis of isoprenoids. Isoprenoids are required for cell survival in most pathogenic bacteria. The researchers targeted the IspH enzyme, essential in isoprenoid biosynthesis. They screened several million commercially available compounds using computer models to find ones that could bind with the enzyme and chose the most potent ones. Most IspH inhibitors cant penetrate the bacterial cell wall, so the researchers worked to identify and synthesize novel IspH inhibitors that could get inside the bacteria.

Rhesus Macaque Genome Reference Includes 85 Million Genetic Variants

Researchers at Baylor College of Medicine, the University of Missouri and the University of Washington created a new reference genome assembly, identifying more than 85 million genetic variants in the rhesus macaque. This makes it the largest database of genetic variation for any single nonhuman primate species. It is a big improvement over the first reference assembled in 2007, and they believe it can help analyze and answer fundamental questions in molecular genetics, cell biology and physiology, not just in rhesus macaques, but in humans and other primates and mammals.

This is a major step forward in the amount of information we have about genetic variation in the rhesus macaque, said Jeffrey Rogers, associate professor at the Human Genome Sequencing Center and Department of Molecular and Human Genetics at Baylor. We have actually identified thousands of new mutations in the population of research animals. Now colleagues all over the country who are investigating various aspects of health and disease using rhesus macaques can begin to make use of that information.

Common Diabetes Drug Linked to Rare COVID-19 Complications

Although diabetes is a known risk factor for COVID-19, researchers with Brigham and Women's Hospital have identified a rare COVID-19 complication with common diabetes drugs. The side effect is called euDKA, or euglycemic diabetic ketoacidosis. DKA occurs when the bodys cells do not absorb enough glucose and begin metabolizing fats instead, which results in a build-up of ketones. EuDKA is marked by lower blood sugar levels, making it harder to diagnose. The researchers evaluated five unusual euDKA cases that was a significantly higher level of incidence, all seen in COVID-19 patients taking sodium-glucose cotransporter 2 inhibitors (SLGLT2i). They believe that COVID-19 may increase the risk of euDKA by binding to cells on the pancreas that produce insulin. The three SGLT2 inhibitors approved by the FDA are Janssens Invokana (canagliflozin), AstraZenecas Farxiga (dapagliflozin) and Eli Lilly and Boehringer Ingelheims Jardiance (empagliflozin).

Whats Going on in the International Space Station?

The Expedition 64 crew took the day off for Christmas, but immediately afterwards went back to work on a variety of biological and medical research. Two studies evaluated new treatments for joint injuries and cancerone looked at bone, cartilage and synovium in artificial gravity chambers to better understand bone loss and joint damage; the second studied protein crystals grown in space and their ability to target cancer cells. A different study on several dozen mice evaluated the vascular changes in space on eyesight functionabout 40% of people working in space have vision changes from fluid shifts and radiation. Another experiment studied genetic changes in space and their impact on the growth and deterioration of bone tissue.

The rest is here:
Research Roundup: Different Antibody Responses to COVID-19 and More - BioSpace

Global Cell And Tissue Analysis Products Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 – The Courier

The primary aim of the globalCell And Tissue Analysis Products Marketresearch report is to evaluate, describe, and forecast the Cell And Tissue Analysis Products market globally based on the various factors like organization size, region, service, application, segments, deployment mode, and verticals. The global Cell And Tissue Analysis Products market research report distinctly evaluates every segment {Cell & Tissue Characterization Products, Bio specimens, Cell Separation Products}; {Drug Discovery and Development, Stem Cell Research, Cell Biology, Other Research Practices} influencing the growth factors, restraining factors for the growth, contribution to the total Cell And Tissue Analysis Products market and the future developments.

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 onCell And Tissue Analysis Products Market Size

Get Free Sample of this Cell And Tissue Analysis Products Report Here:https://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#RequestSample

The global Cell And Tissue Analysis Products market research report consists of the following:

The detail meaning of the Cell And Tissue Analysis Products market, which helps to evaluate and understand the market and its applications on a global level.

The Cell And Tissue Analysis Products market is segmented into the detailed segments and has been evaluated thoroughly for better understanding and analysis of the market.

To be in the competitive position, the global Cell And Tissue Analysis Products market research report provides full coverage of the factors contributing to the growth of the Cell And Tissue Analysis Products market, factors which are hampering the growth rate and the reason of such an activity is also evaluated briefly in the report so that Cell And Tissue Analysis Products market players can take decisions.

Cell And Tissue Analysis Products Market COVID-19 Impact Analysis

The outbreak of COVID-19 was sudden and was not at all considered so dangerous when it first struck at Wuhan city of China. Although, everything in that city was closed but the coronavirus infection had wide spread in China as a wild fire. Within months it spread to the neighboring countries and then to every single country in the world. The World Health Organization announced it as a pandemic and till then it had created huge losses in several countries.

Read Detailed Index of full Research Study at:https://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478

Summary

The global Cell And Tissue Analysis Products market research report gives a comprehensive data and analysis about the worldwide market. The report further gives the data that one could rely on; which comes with in-depth analysis of Cell And Tissue Analysis Products market. Different factors like in-depth description of Cell And Tissue Analysis Products market, growth factors, segmentation, regional analysis, sales, supply, demand, manufacture analysis, recent trends, and competing companies are included in the Cell And Tissue Analysis Products report. The exquisite data provided in global Cell And Tissue Analysis Products market research report is explanatory in terms of quantity as well as quality.

Other Points Covered In The Global Cell And Tissue Analysis Products Market Research Report

The global Cell And Tissue Analysis Products market research report also states the present opportunities in the market and future possibilities present in the market.

All the necessary methods for collecting the data were used and required methodology as per the research was used to get to the results for the analysis.

The global Cell And Tissue Analysis Products market research report consists of porter Five Forces model and SWOT analysis. For the validations of the data both Top-down method and Bottom-up method were used.

All the major players Danaher, Luminex, EMD Millipore Corporation, PARTEC, GE Healthcare, Thermo Fisher Scientific, BD, Mindray, PerkinElmer, Miltenyi Biotec leading in the Cell And Tissue Analysis Products market are mentioned in the report along with their regions-wise dominance.

A detail region-wise segmentation is also been involved in the global Cell And Tissue Analysis Products market research report to make a clear.

For more information on this Cell And Tissue Analysis Products Report, Inquiry Here:https://www.marketresearchstore.com/report/global-cell-and-tissue-analysis-products-market-report-289478#InquiryForBuying

See more here:
Global Cell And Tissue Analysis Products Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier

Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It’s Like Smart Bomb Technology in the Lung – SciTechDaily

Umbilical cord-derived mesenchymal stem cells naturally migrate directly to the lung where they begin repair to COVID-19 damage. Credit: Dr. Camillo Ricordi

Study looked at treating severe COVID-19 with umbilical-cord derived mesenchymal stem cells.

University of Miami Miller School of Medicine researchers led a unique and groundbreaking randomized controlled trial showing umbilical cord derived mesenchymal stem cell infusions safely reduce risk of death and quicken time to recovery for the severest COVID-19 patients, according to results published inSTEM CELLS Translational Medicinein January 2021.

The studys senior author, Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine, said treating COVID-19 with mesenchymal stem cells makes sense.

The paper describes findings from 24 patients hospitalized at University of Miami Tower or Jackson Memorial Hospital with COVID-19 who developed severe acute respiratory distress syndrome. Each received two infusions given days apart of either mesenchymal stem cells or placebo.

It was a double-blind study. Doctors and patients didnt know what was infused, Dr. Ricordi said. Two infusions of 100 million stem cells were delivered within three days, for a total of 200 million cells in each subject in the treatment group.

Researchers found the treatment was safe, with no infusion-related serious adverse events.

Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine. Credit: University of Miami Health System

Patient survival at one month was 91% in the stem cell treated group versus 42% in the control group. Among patients younger than 85 years old, 100% of those treated with mesenchymal stem cells survived at one month.

Dr. Ricordi and colleagues also found time to recovery was faster among those in the treatment arm. More than half of patients treated with mesenchymal stem cell infusions recovered and went home from the hospital within two weeks after the last treatment. More than 80% of the treatment group recovered by day 30, versus less than 37% in the control group.

The umbilical cord contains progenitor stem cells, or mesenchymal stem cells, that can be expanded and provide therapeutic doses for over 10,000 patients from a single umbilical cord. Its a unique resource of cells that are under investigation for their possible use in cell therapy applications, anytime you have to modulate immune response or inflammatory response, he said. Weve been studying them with our collaborators in China for more than 10 years in Type 1 Diabetes, and there are currently over 260 clinical studies listed in clinicaltrials.gov for treatment of other autoimmune diseases.

Mesenchymal cells not only help correct immune and inflammatory responses that go awry, they also have antimicrobial activity and have been shown to promote tissue regeneration.

Our results confirm the powerful anti-inflammatory, immunomodulatory effect of UC-MSC. These cells have clearly inhibited the cytokine storm, a hallmark of severe COVID-19, said Giacomo Lanzoni, Ph.D, lead author of the paper and assistant research professor at the Diabetes Research Institute. The results are critically important not only for COVID-19 but also for other diseases characterized by aberrant and hyperinflammatory immune responses, such as autoimmune Type 1 Diabetes.

When given intravenously, mesenchymal stem cells migrate naturally to the lungs. Thats where therapy is needed in COVID-19 patients with acute respiratory distress syndrome, a dangerous complication associated with severe inflammation and fluid buildup in the lungs.

It seemed to me that these stem cells could be an ideal treatment option for severe COVID-19, said Dr. Ricordi, Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, and professor of biomedical engineering, microbiology and immunology. It requires only an intravenous (IV) infusion, like a blood transfusion. Its like smart bomb technology in the lung to restore normal immune response and reverse life-threatening complications.

When the pandemic emerged, Dr. Ricordi asked collaborators in China if they had studied mesenchymal stem cell treatment in COVID-19 patients. In fact, they and Israeli researchers reported great success treating COVID-19 patients with the stem cells, in many cases with 100% of treated patients surviving and recovering faster than those without stem cell treatment.

But there was widespread skepticism about these initial results, because none of the studies had been randomized, where patients randomly received treatment or a control solution (placebo), to compare results in similar groups of patients.

We approached the FDA and they approved our proposed randomized controlled trial in one week, and we started as quickly as possible, Dr. Ricordi said.

Dr. Ricordi worked with several key collaborators at the Miller School, the University of Miami Health System, Jackson Health System, and collaborated with others in the U.S. and internationally, including Arnold I. Caplan, Ph.D., of Case Western Reserve University, who first described mesenchymal stem cells.

The next step is to study use of the stem cells in COVID-19 patients who have not yet become severely ill but are at risk of having to be intubated, to determine if the infusions prevent disease progression.

The findings have implications for studies in other diseases, too, according to Dr. Ricordi.

Hyper-immune and hyper-inflammatory responses in autoimmune diseases might share a common thread with why some COVID-19 patients transition to severe forms of the disease and others dont.

Autoimmunity is a big challenge for healthcare, as is COVID-19. Autoimmunity affects 20% of the American population and includes over 100 disease conditions, of which Type 1 Diabetes can be considered just the tip of the iceberg. What we are learning is that there may be a common thread and risk factors that can predispose to both an autoimmune disease or to a severe reaction following viral infections, such as SARS-CoV-2, he said.

The DRI Cell Transplant Center is planning to create a large repository of mesenchymal stem cells that are ready to use and can be distributed to hospitals and centers in North America, he said.

These could be used not only for COVID-19 but also for clinical trials to treat autoimmune diseases, like Type 1 Diabetes, Dr. Ricordi said. If we could infuse these cells at the onset of Type 1 Diabetes, we might be able to block progression of autoimmunity in newly diagnosed subjects, and progression of complications in patients affected by the disease long-term. We are planning such a trial specifically for diabetes nephropathy, a kidney disease that is one of the major causes of dialysis and kidney transplantation. We are also planning to do a study on umbilical cord mesenchymal stem cell transplantation in combination with pancreatic islets to see if you can modulate the immune response to an islet transplant locally.

Funding by The Cure Alliance made launching the initial trial possible, while a $3 million grant from North Americas Building Trades Unions (NABTU) allowed Dr. Ricordi and colleagues to complete the clinical trial and expand research with mesenchymal stem cells.

North Americas Building Trades Unions (NABTU) has been a major supporter of the Diabetes Research Institute since 1984, when they started a campaign to fund, and build, our state-of-the-art research and treatment facility. NABTU has continued to support our work through the years, including our mesenchymal stem cell research that helped lead the way to this clinical trial, he said.

Reference: 5 January 2021, STEM CELLS Translational Medicine.

All the organizations funding the research are nonprofit entities, including the Barilla Group and Family, The Fondazione Silvio Tronchetti Provera, the Simkins Family Foundation and the Diabetes Research Institute Foundation. The National Center for Advancing Translational Sciences also provided funding.

Coauthors on the NEJM paper include: Giacomo Lanzoni, Ph.D., assistant research professor, DRI; Elina Linetsky, Ph.D., DRI director of quality assurance and regulatory affairs; Diego Correa, M.D., Ph.D., assistant professor (Research) Dept. of Orthopaedics and the DRI, adjunct assistant professor of biology at Case Western Reserve University; Shari Messinger Cayetano, Ph.D., associate professor of Public Health Sciences at the Miller School; Roger A. Alvarez, D.O., M.P.H., a pulmonologist with UHealth Pulmonary and Sleep Medicine; Antonio C Marttos, M.D., a UHealth general surgeon; Ana Alvarez Gil, DRI; Raffaella Poggioli, M.D., DRI; Phillip Ruiz, M.D., Ph.D., department of Surgery at the Miller School and the UHealth Anatomic Pathology department; Khemraj Hirani, M.Pharm., Ph.D., R.Ph., CCRP, CIP, RAC, M.B.A., director of regulatory affairs and quality assurance at the DRI; Crystal A. Bell, department of medicine at the Miller School; Halina Kusack, department of Medicine, Miller School; Lisa Rafkin, research assistant professor, DRI; Rodolfo Alejandro, M.D., professor of Medicine at the Miller School, co-director of the Cell Transplant Center, and director/attending physician of the Clinical Cell Transplant Program at the DRI; David Baidal, M.D., assistant professor of Medicine in the division of Endocrinology, Diabetes & Metabolism at the Miller School and member of the DRIs Clinical Islet Transplant Program; Andrew Pastewski, M.D., Jackson Health System; Kunal Gawri, Miller School and University of Miami Health System; Dimitrios Kouroupis, postdoctoral research fellow at the Miller School; Clarissa Leero, DRI; Alejandro M.A. Mantero, Ph.D., lead research analyst, department of Health Sciences at the Miller School; Xiaojing Wang, DRI; Luis Roque, DRI; Burlett Masters, DRI; Norma S. Kenyon, Ph.D., deputy director and the Martin Kleiman professor of Surgery, Microbiology and Immunology and Biomedical Engineering at the DRI; Enrique Ginzburg, M.D., chief of Surgery at University of Miami Hospital and Trauma Medical Director at Jackson South Community Hospital; Xiumin Xu, DRI; Jianming Tan, M.D., Ph.D., Fuzhou General Hospital, Fujian, China; Arnold I. Caplan, Ph.D., professor of Biology at Case Western Reserve University; and Marilyn Glassberg, M.D., division chief of Pulmonary Medicine, Critical Care and Sleep Medicine at the University of Arizona College of Medicine.

Continue reading here:
Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily

New clues on why pregnancy may increase risk of organ transplant rejection – Newswise

Newswise A research study at the University of Chicago has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that produces antibodies (known as the humoral response) becomes sensitized, creating memory B cells that can later contribute to the rejection of a transplanted organ.

The results help to clarify why it is that the immune system can tolerate a fetus during pregnancy, but later may be more likely to become sensitized to and reject an organ transplant. The study was published on January 4, 2021 in the Journal of Clinical Investigation.

The immune system is designed to respond to and protect against foreign invaders; it does this by recognizing molecules on foreign cells, known as antigens, and mounting an immune response that produces T cells to target and attack foreign cells directly, as well as memory B cells that produce antibodies to tag foreign cells for destruction by other blood cells.

In most cases, this system is extremely beneficial but in pregnancy, some adaptation is required to prevent the rejection of a fetus, which only shares half its genes with the mother and therefore presents foreign antigens to the mothers immune system.

This also has the paradoxical effect of increasing the risk of a rejection for a transplanted organ (or allograft) after a person has given birth, particularly if the transplanted organ such as a kidney is from the father of their children.

This new research was inspired by prior work showing that T cells become tolerized during pregnancy, meaning they dont respond to fetal antigens. This was paradoxical to the transplant field, where we consider pregnancy a sensitizing event, said co-senior author Anita Chong, PhD, a professor of surgery at UChicago. I wanted to know why it was that pregnancy resulted in sensitization to an allograft (transplanted organ) from the male partner, but enhanced tolerance to a fetus expressing the same antigens.

In the study, the investigators examined the immune response of female mice after receiving a transplanted heart from one of their offspring. By tracking both the T cell response and the humoral response, they could follow both arms of the immune response and study their effects on transplant rejection. They saw that the T cells did not react to the allograft, but the memory B cells did, producing antibodies against foreign antigens from the transplanted heart.

Our assumption was that both arms of the immune system would be sensitized to the offspring-matched transplanted organ, said Chong, But theres something about the fetus promoting T cell tolerance that is also preserved for the allograft. On the other hand, the antibodies that are produced to the fetus do not harm the fetus, but cause the rejection of the allograft.

Given the biology of pregnancy, the investigators say, these results make sense.

Pregnancy cannot evolve to completely eliminate the humoral response because its critical for a mother to be able to produce antibodies against infectious pathogens during pregnancy and breastfeeding; its the only immunity a mother can pass to their child. So, the immune system is primed to make antibodies against anything foreign during this period, including those expressed by the fetus, said Chong. As a result, the placenta has evolved ways to handle these antibodies in order to prevent fetus rejection in subsequent pregnancies.

These results are a promising start for preventing transplant rejection in people after pregnancies in the future.

There is potential for applying therapies that would eliminate memory B cells and antibodies that now make it more difficult for these women to accept a transplant, said co-senior author Maria-Luisa Alegre, MD/PhD, a professor of medicine at UChicago. This would level the playing field for women with children. We could eliminate antibodies and B cells before transplantation and eliminate the problem, while T cell responses to antigens shared by the fetus and the transplant would already be spontaneously partially suppressed.

What is not yet clear is how the sensitized humoral response overrides the T cell tolerance to reject an allograft in people after pregnancy, or how the T cell tolerance might be induced in non-mothers in order to prevent rejection in other populations.

As part of their ongoing collaboration, Chong and Alegre hope to continue working on this puzzle. One aspect of future research is to see if we can exploit this ability of pregnancy to tolerize T cells to have better acceptance not only in people who have been pregnant, but in everybody, said Alegre. Outside of pregnancy, people can get sensitized prior to transplantation in different ways, from disease or environmental antigens, and it can be difficult to protect the transplant from cross-reactive memory T cells. Now were looking at how pregnancy can tolerize these memory T cells that are otherwise difficult to immunosuppress with current drugs.

The study, Pregnancy-induced humoral sensitization overrides T cell tolerance to fetus-matched allografts in mice, was supported by NIH/NIAID grants R01AI142747 and P01AI097113. Additional authors include Ashley N. Suah, Dong-Kha V. Tran, Stella H.W. Khiew, Michael S. Andrade, Jared M. Pollard, Dharmendra Jain, James S. Young, and Dengping Yin of UChicago; and Geetha Chalasani of the University of Pittsburgh.

###

About the University of Chicago Medicine & Biological Sciences

The University of Chicago Medicine, with a history dating back to 1927, is one of the nations leading academic health systems. It unites the missions of the University of Chicago Medical Center, Pritzker School of Medicine and the Biological Sciences Division. Twelve Nobel Prize winners in physiology or medicine have been affiliated with the University of Chicago Medicine. Its main Hyde Park campus is home to the Center for Care and Discovery, Bernard Mitchell Hospital, Comer Childrens Hospital and the Duchossois Center for Advanced Medicine. It also has ambulatory facilities in Orland Park, South Loop and River East as well as affiliations and partnerships that create a regional network of care. UChicago Medicine offers a full range of specialty-care services for adults and children through more than 40 institutes and centers including an NCI-designated Comprehensive Cancer Center. Together with Harvey-based Ingalls Memorial, UChicago Medicine has 1,296 licensed beds, nearly 1,300 attending physicians, over 2,800 nurses and about 970 residents and fellows.

Visit UChicago Medicines health and science news blog at http://www.uchicagomedicine.org/forefront.

Twitter @UChicagoMed Facebook.com/UChicagoMed

Facebook.com/UChicagoMedComer

Read more:
New clues on why pregnancy may increase risk of organ transplant rejection - Newswise

This Was the Busiest Year for IPOs Since the Dot-Com Bubble. Expect Another Busy Year in 2021. – Barron’s

Text size

In 2020, a soaring IPO market not only rebounded from the Covid-19 pandemic that nearly killed it, but also posted its busiest year since 1999. Initial public offerings arent taking much of a holiday breather, with some deals expected to launch the week of Jan. 4

More than twice as many companies went public this year compared with 2019, while valuations jumped 168%. According to Dealogic, 456 U.S. IPOs raised $167.4 billion as of Dec. 24, compared to $62.5 billion collected by 211 companies for the same period in 2019.

Thats the most new issues produced by the IPO market in 20 years. In 1999, a rousing time for new issues when hundreds of companies sought to tap the public equities markets, 547 offerings collected $107.9 billion, Dealogic said.

The IPO door opened and a flood of activity went through. The outperformance of early offerings in the aftermarket created a huge degree of momentum for others to follow, said Jim Cooney, head of Americas equity capital markets at Bank of America.

The increase in IPOs this year was due to a surging U.S. stock market that powered through Covid-19 volatility and jitters around the U.S. presidential election. Public markets rewarded growth over profitability in 2020, Christina Roupas, a partner and co-chair of capital markets at law firm Winston & Strawn, said. High growth, net-loss companies and other start-ups that never would have been viable IPO candidates in prior years, all of a sudden had investors willing to throw money at them that perhaps would only have been available previously in the private markets and at less desirable valuations, she said.

By far the biggest story of this years IPO market was the success of special purpose acquisitions, or SPACs. There were 248 blank check companies that went public in 2020more than half the number of all IPOs this yearraising $82.3 billion. Thats nearly 50% of the $167.4 billion raised this year by the IPO market.

SPACs also delivered the years biggest offering: Pershing Square Tontine Holdings (ticker: PSTH), a $4 billion so-called blank-check company headed by Bill Ackman, the founder of Pershing Square Capital Management. Investors continue to provide significant capital to a diverse group of sponsors given [that] these offerings are working incredibly well, Cooney said of SPACs. With few exceptions, the majority of clients should be evaluating this opportunity.

The technology sector was quiet during the first half of 2020, but came roaring out of the gate during the last six months of the year. There were 65 tech IPOs this year, valued at $38.7 billion, Dealogic said. Tech also delivered four of the five biggest IPOs this year: Snowflake (SNOW), which raised $3.86 billion; Airbnbs (ABNB) $3.83 billion offering; DoorDashs (DASH) $3.37 billion deal; and Lufax Holding (LU), which raised $2.69 billion.

The other big story in the IPO market? Health care. The sector produced 102 IPOs this year, valued at $24.8 billion, the second most by number and third biggest by value. Much of health cares success was due to the biotech industry, which saw a surge in deals. Three-fourths of health-care IPOs were biotechs, raising $20.1 billion, Dealogic said. Investors, and the public, realized the importance of biotechnology and life science research as companies raced to develop a cure for Covid-19 this year, executives said. Its the golden age of drug discovery and thats been recognized broadly by the investment community, said BofAs Cooney.

Covid-19 buzz helped some biotechs and life sciences surge, delivering three of the top five best performing offerings this year. CureVac (CVAC), a German biotech that develops vaccines for infectious disease, soared nearly 250% in August. Berkeley Lights (BLI), a digital cell biology company, rocketed nearly 198% in July, while Seer (SEER), which develops tools to analyze proteomics, jumped 197.16% earlier this month.

Anything that is going to help solve the current health crisis, anything health-related is in high demand right now, said Chris Malik, a managing director at KeyBanc Capital Markets.

Next year, expect technology and health care IPOs to continue dominating the market and SPACs to remain aggressive, executives said. Several well-known companies are anticipated to go public in 2021 including Marqeta, Bumble, Roblox, Robinhood Markets, Affirm Holdings, Coinbase, Poshmark and Oscar Health.

The IPO market isnt taking much time off. Due to speedy virtual roadshows, management teams can now market their companies to investors through virtual meetings in three to five days, down from the eight to 10 days typically needed for in-person roadshows. We expect the strength and momentum in IPOs to continue in 2021, with numerous clients targeting IPO launches as early as the first week of the year, BofAs Cooney said.

Write to Luisa Beltran at luisa.beltran@dowjones.com

Read more:
This Was the Busiest Year for IPOs Since the Dot-Com Bubble. Expect Another Busy Year in 2021. - Barron's

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million…

PITTSBURGH, Dec. 30, 2020 /PRNewswire/ --LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application.Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).

In addition, LyGenesis just completed over $11 million in private financing of convertible notes led by Juvenescence, Ltd. and Longevity Vision Fund. Proceeds will be used to fund LyGenesis's Phase 2a clinical trial with a first patient in targeted for early 2021, as well as to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs, including pancreas, kidney, and thymus regeneration.

"The FDA clearance for our IND and the start of our Phase 2a study in patients with ESLD is a testimony to our robust preclinical research program, the unmet need in advanced liver disease, and our novel approach to organ regeneration. Moreover, the lack of genetic manipulation, ease of administration, and low cost of goods for our cell therapy forms the foundation for a promising and scalable first commercial product," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis.

"LyGenesis's progress has been simply extraordinary. They have recently published 4 peer-reviewed papers on their regenerative medicine technology, filed and received clearance for their first IND, identified a primary site for their Phase 2a clinical trial, and now have closed a round of financing to ensure they have the cash to run their trial and also progress additional cell therapies toward the clinic," said Jim Mellon, Co-Founder of Juvenescence, and Chair of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "We are excited to support LyGenesis in its vision to tackle some of the most challenging unmet medical needs of our time with a unique organ regeneration technology. By enabling one donated organ to act as a source of therapies for dozens of patients, LyGenesis is on the cusp of disrupting the supply-demand calculus of organ donation, and this regulatory clearance from the FDA is a definitive milestone in their evolution."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Ltd. is a life sciences company developing therapies to modify aging increasing human health span and longevity. It was founded byJim Mellon,Dr. Gregory BaileyandDr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the pharmaceutical and consumer health sectors. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvlabs.com.

About Longevity Vision FundLongevity Vision Fund is a venture capital fund that invests in technologies with the potential to disrupt life sciences to help people live longer and healthier lives. The fund is focused on early diagnostics, AI in healthcare, and advanced therapeutic platforms targeting aging and age-related diseases. It was founded by Sergey Young, a venture capital investor with a mission to make longevity more accessible and affordable. Sergey is also an Innovation Board member at XPRIZE Foundation and a development sponsor of Age Reversal XPRIZE. To learn more, please visit lvf.vc.

Contact InformationMichael Hufford(858) 603-2514262126@email4pr.com

View original content:http://www.prnewswire.com/news-releases/lygenesis-receives-fda-clearance-to-begin-phase-2a-trial-of-its-cell-therapy-for-patients-with-end-stage-liver-disease-and-also-closes-11-million-convertible-debt-financing-301199042.html

SOURCE LyGenesis, Inc.

More here:
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million...

COVID-19 Impact on Live Cell Imaging Consumables Market Size, Share, Trends and Analysis 2020 to 2026| Carl Zeiss AG (Germany), Olympus Corporation…

Global Live Cell Imaging Consumables Market Forecast to 2026.

Market Report Expert has published a statistical analysis, titled as Live Cell Imaging Consumables Market. The global Live Cell Imaging Consumables report is a valuable source of accurate data, which is examined to promote better understanding of the business scenario. To present the effective statistics of businesses, analyst uses the qualitative and quantitative techniques. The major key pillars, which are responsible for the growth of the companies are mentioned with details. It provides the Live Cell Imaging Consumables industry overview along with its limitations and scope.

Under COVID-19 Outbreak, how the Live Cell Imaging Consumables Industry will develop is also analyzed in detail in COVID Impact Chapter of this report.

For Better Understanding, Download FREE Sample Copy of Live Cell Imaging Consumables Market Report(Including full TOC, Graphs, Sample Data, and Tables)@ https://www.marketreportexpert.com/report/Live Cell Imaging Consumables/807/sample

Some of top players influencing the Global Live Cell Imaging Consumables market:

Carl Zeiss AG (Germany), Olympus Corporation (Japan), Molecular Devices, LCC (US), Leica Microsystems (Germany), Becton, Dickinson and Company (US), Nikon Corporation (Japan), Thermo Fisher Scientific, Inc.(US), GE Healthcare (U.K.), PerkinElmer, Inc. (US), Sigma Aldrich Corporation (US)

Scope of the Live Cell Imaging Consumables Market Report:

The Global Live Cell Imaging Consumables market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Live Cell Imaging Consumables market. The report focuses on well-known providers in the global Live Cell Imaging Consumables industry, market segments, competition, and the macro environment. Different industries are profiled for getting the current scenario of various working methodologies and policies of the businesses. Global regions such as Latin America, North America, China, Japan, Asia Pacific, and India are considered to study the layout of the various industries. This innovative report provides point to point analysis of the dynamic environment and throws light on the recent innovations, to understand all the current strategies of the industries.

Note: We can provide market report in regional language too, German/French/Japanese. We have researched the situation of COVID-19 thoroughly and Our new sample has been updated to reflect COVID-19 Impact on industry trends. We also offer a 25% discount.

Depending on the end users and applications, it focuses on the segments to increase the customers rapidly. It comprises top driving factors along with the opportunities, which are beneficial to provide insights into the businesses. Additionally, restraints are also mentioned to give a clear picture of risks that can limit the growth of the businesses.

Majortype, primarily split into

Assay Kits, Reagents, Media, Others

Major applications/end users, including

Cell Biology, Stem Cells, Developmental Biology, Drug Discovery

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends.): https://www.marketreportexpert.com/report/Live Cell Imaging Consumables/807/inquiry

This report examines all the key factors influencing growth of global Live Cell Imaging Consumables market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Live Cell Imaging Consumables market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions:

Regionally, this market has been inspected across various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, and Europe on the basis of productivity and manufacturing base. Some significant key players have been profiled in this research report to get an overview and strategies carried out by them. Degree of competition has been given by analyzing the global Live Cell Imaging Consumables market at domestic as well as a global platform. This global Live Cell Imaging Consumables market has been examined through industry analysis techniques such as SWOT and Porters five techniques.

Globally, this market focuses on some particular strategies to progress the growth of these industries. To understand the existing structure and scenario of various companies, major key strategies are examined in this report. Different regions are examined to give a clear idea of various terms, such as current trends, size, and shares along with the productivity of industries.

Finally, it focuses on some needs of the customers and quality of services, which helps in balancing Live Cell Imaging Consumables of the industries.

Get Table of Content, Tables, and Figures of Live Cell Imaging Consumables Market Report: https://www.marketreportexpert.com/report/Live Cell Imaging Consumables/807/tableofcontent

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Live Cell Imaging Consumables market?What was the size of the emerging Live Cell Imaging Consumables market by value in 2020?What will be the size of the emerging Live Cell Imaging Consumables market in 2026?Which region is expected to hold the highest market share in the Live Cell Imaging Consumables market?What trends, challenges and barriers will impact the development and sizing of the Global Live Cell Imaging Consumables market?What is sales volume, revenue, and price analysis of top manufacturers of Live Cell Imaging Consumables market?What are the Live Cell Imaging Consumables market opportunities and threats faced by the vendors in the global Live Cell Imaging Consumables Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Live Cell Imaging Consumables market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]Web:-https://www.marketreportexpert.com

See the original post here:
COVID-19 Impact on Live Cell Imaging Consumables Market Size, Share, Trends and Analysis 2020 to 2026| Carl Zeiss AG (Germany), Olympus Corporation...

Global Live Cell Imaging Consumables Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2026 – LionLowdown

Global Live Cell Imaging Consumables Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 watchfully analyzes and researches the industry status and outlook of the market. The report provides a comprehensive analysis of the industry status and outlook of major regions based on key players, countries, product types, and end industries. This recent research presentation on the global Live Cell Imaging Consumables market offers exclusive information on the various concurrent developments and events prevalent in the global market and their subsequent consequences on a holistic growth trajectory. The report determines an explicit analysis of global market share analysis for the new entrants & top industry players, regional and country level segments, opportunities, challenges, threats investment opportunities. Well-experienced industry analysts analyze the market size, growth opportunities, applications, companies, and supply chains.

Readers Are Expected To Understand The Following Market Scenarios:

Global Live Cell Imaging Consumables market research reports consist of information according to the manufacturers, regions, types, and applications. Readers are also equipped with assorted knowledge spots pertaining to product and service-oriented developments besides evaluating their applicability across sectors and geographies. The report entails various growth enablers, prominent trends, factors as well as market-specific challenges, limitations, and threat probabilities. The research distinctively segregates the competition spectrum into frontline players and moderate and contributing players having local dominance.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/13115

Global And Regional Prospects:

Some of the following top market players profile included in this report: Carl Zeiss AG (Germany), Olympus Corporation (Japan), Molecular Devices, LCC (US), Leica Microsystems (Germany), Becton, Dickinson and Company (US), Nikon Corporation (Japan), Thermo Fisher Scientific, Inc.(US), GE Healthcare (U.K.), PerkinElmer, Inc. (US), Sigma Aldrich Corporation (US)

By the product type, the market is primarily split into: Assay Kits, Reagents, Media, Others,

By the end-users/application, this report covers the following segments: Cell Biology, Stem Cells, Developmental Biology, Drug Discovery,

The report covers different geographical areas: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-live-cell-imaging-consumables-market-13115

Moreover, the report contains the discussion over the market regarding the total revenue generation by the global Live Cell Imaging Consumables market at the global level, along with the manufacturing techniques and cost, demand, and supply of a generated product or offered services, capacity, consumption, and other related information. The total cost spent on manufacturing the product and analysis of its assembling procedure is also mentioned in the report. The analysis study includes market size and forecast by type and by application segment in terms of sales and revenue for the period 2015-2025.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Here is the original post:
Global Live Cell Imaging Consumables Market Tendencies, Revenue Forecast and Interesting Opportunities from 2020 to 2026 - LionLowdown

Scientists Discover a Gene to Stay Thin Protects Against Diet-Induced Obesity – SciTechDaily

By Institute of Molecular Biotechnology of the Austrian Academy of SciencesDecember 27, 2020

Why some people eat as much as they want and stay lean while others cant. In mice, genetic deletion of ALK resulted in thin animals with marked resistance to diet induced obesity while food intake was not changed. The researchers found that ALK in the hypothalamus controls energy expenditure via sympathetic control of adipose tissue lipolysis. The drawing illustrates how our genetic make-up determines body weight (gain). Credit: IMBA/IMP graphics

A noticeable impact on the waistline of many people is a side-effect of the quarantine due to the global COVID-19 outbreak. Reduced activity and lack of sports while consuming the same, or even elevated amounts of calories can quickly cause a substantial weight gain.

Strikingly, some individuals can make it through this period without gaining any weight we all know these people who can eat what they want but do not appear to gain weight.

A consortium of international researchers including scientists from IMBA, the University of British Columbia, Medical University of Vienna, and the Estonian Biobank have now taken a unique approach: thus far, the regulation of fat metabolism has mainly focused on finding genes linked to obesity. The team, however, went on a quest to discover genes linked to thinness, or the resistance to weight gain.

In order to identify candidate thinness genes, the research team conducted genome-wide association studies in an Estonian population cohort, profiling over 47,000 people. They compared thin to control individuals and were thereby able to pinpoint ALK, which codes for Anaplastic Lymphoma Kinase, as a candidate gene for thinness. ALK was mainly known due to its involvement in cancer, as it is frequently mutated in multiple cancers. However, its physiological function was largely elusive.

To test the hypothesis of ALK being involved in thinness, the researchers inactivated the ALK gene in mice. Strikingly, despite normal food intake and activity, ALK deficient mice were skinnier because of a much-reduced fat mass and strikingly protected against diet-induced obesity as opposed to littermate controls. Interestingly, when knocking down the ALK orthologues in the fruit fly Drosophila melanogaster, they also found significantly lower triglyceride fat accumulation, even when flies were fed a high-sucrose diet.

First author Michael Orthofer from the Penninger lab explains: By using a technique called indirect calorimetry, we could show that ALK deficient mice exhibit increased energy expenditure. This means that they burn more calories than normal mice and explains why they remain thin even if they eat the same amount of food. In addition to that, these animals also show improved glucose tolerance.

ALK is highest expressed in a very specific brain region called the paraventricular nucleus (PVN) of the hypothalamus. When the scientists depleted ALK in this brain area, a similar body weight reduction was observed compared to full-body ALK knockout models. The PVN is known to be involved in the regulation of energy homeostasis, both via hormonal pathways and the sympathetic nervous system, which uses norepinephrine as neurotransmitter. Indeed, levels of the neurotransmitter norepinephrine were elevated in both white and brown fat of the mutant mice, indicating that ALK deficiency increases sympathetic tone to adipose tissues. Consequently, ALK knockout mice showed increased breakdown of fat, which explains their low body adiposity and resistance to weight gain.

This strengthens the notion that ALK is indeed part of a larger brain circuit involved in energy expenditure. We are very excited about these results on the genetics of thinness and will further investigate the mechanisms of how ALK-expressing neurons are able to control weight. Our results also highlight the important therapeutic potential of ALK inhibition, says Josef Penninger, IMBA group leader and founding director, who is now director of the Life Sciences Institute of the University of British Columbia.

For more on this research, read Scientists Identify Gene Linked to Thinness.

Reference: Identification of ALK in Thinness by Michael Orthofer, Armand Valsesia, Reedik Mgi, Qiao-Ping Wang, Joanna Kaczanowska, Ivona Kozieradzki, Alexandra Leopoldi, Domagoj Cikes, Lydia M. Zopf, Evgenii O. Tretiakov, Egon Demetz, Richard Hilbe, Anna Boehm, Melita Ticevic, Margit Nukas, Alexander Jais, Katrin Spirk, Teleri Clark, Sabine Amann, Maarja Lepamets, Christoph Neumayr, Cosmas Arnold, Zhengchao Dou, Volker Kuhn, Maria Novatchkova, Shane J.F. Cronin, Uwe J.F. Tietge, Simone Mller, J. Andrew Pospisilik, Vanja Nagy, Chi-Chung Hui, Jelena Lazovic, Harald Esterbauer, Astrid Hagelkruys, Ivan Tancevski, Florian W. Kiefer, Tibor Harkany, Wulf Haubensak, G. Gregory Neely, Andres Metspalu, Jorg Hager, Nele Gheldof and Josef M. Penninger, 21 May 2020, Cell.DOI: 10.1016/j.cell.2020.04.034

IMBA Institute of Molecular Biotechnology is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is located at the Vienna BioCenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. The stem cell and organoid research at IMBA is being funded by the Austrian Federal Ministry of Science and the City of Vienna.

Read more:
Scientists Discover a Gene to Stay Thin Protects Against Diet-Induced Obesity - SciTechDaily

Global Live Cell Imaging Market Proceeds To Witness Huge Upswing Over Assessment Period by 2025 – Factory Gate

The globalLive Cell Imaging Marketresearch report enlists the vital and practical information with regards to market situation. The present scenario of Live Cell Imaging market, along with its previous performance as well as future scope are covered in the report. This eases the users understanding of the market thoroughly, while also gaining knowledge about market opportunities and the dominant players Becton, Dickinson and Company (U.S.), PerkinElmer, Inc. (U.S.), Olympus Corporation (Japan), Nikon Corporation (Japan), GE Healthcare (U.K.), Thermo Fisher Scientific, Inc.(U.S.), Sigma Aldrich Corporation (U.S.), Leica Microsystems (Germany), Carl Zeiss AG (Germany), Molecular Devices, LCC (U.S.) in the Live Cell Imaging market.

Request for a FREE sample of Live Cell Imaging market research report@https://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843#RequestSample

The Global Live Cell Imaging Market Research Report Details

The beginning of the report summarizes the market with the definition of the overall Live Cell Imaging market.

The following section includes Live Cell Imaging market segmentation Equipment, Consumables. Segmentation is done on the basis of application, type, end-user industries, and several such factors among others.

We have strived to include sub-segments Cell Biology, Stem Cells, Developmental Biology, Drug Discovery in segmentation section, wherever possible. Also included are details regarding the dominant segments in the worldwide Live Cell Imaging market.

The global Live Cell Imaging market has also been classified on the basis of regions. On the basis of the regional diversification, details regarding market share and size have also been obtained.

In the succeeding part, growth factors for the Live Cell Imaging market have been elucidated. This section also explains the technological advancements made to improve market size and position. Also enlisted is the information pertaining to the end-use industries for the Live Cell Imaging market.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843

Live Cell Imaging Market COVID-19 Impact Analysis

As the world is still dealing with COVID-19 situation, many of the countries have slowly started to revive its economic situation by starting its trade and businesses. There has been enormous loss in these few months both in terms of economy and human lives. As the WHO has already suggested that there are very less chances that the virus will completely go, hence we will have start living with it. Many of the drug companies are getting positive response of their COVID-19 vaccines, but there is still time for its availability in the global market.

There are 15 Sections to show the global Live Cell Imaging market

Sections 1, Definition, Specifications and Classification of Live Cell Imaging , Applications of Live Cell Imaging , Market Segment by Regions;Section 2, Assembling Cost Structure, Crude Material and Providers, Assembling Procedure, Industry Chain Structure;Sections 3,Technical Data and Manufacturing Plants Analysis of Live Cell Imaging , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Sections 4, Generally Market Analysis, Limit Examination (Organization Fragment), Sales Examination (Organization Portion), sales Value Investigation (Organization Section);Sections 5 and Six, Regional Market Investigation that incorporates United States, China, Europe, Japan, Korea and Taiwan, Live Cell Imaging segment Market Examination (by Sort);Sections 7 and Eight, The Live Cell Imaging Segment Market Analysis (by Application) Major Manufacturers Analysis of Live Cell Imaging ;Sections Nine, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Equipment, Consumables Market Trend by Application Cell Biology, Stem Cells, Developmental Biology, Drug Discovery;Sections 10, Regional Promoting Type Investigation, Worldwide Exchange Type Examination, Inventory network Investigation;Sections 11, The Customers Examination of global Live Cell Imaging;Sections 12, Live Cell Imaging Research Findings and Conclusion, Appendix, system and information source;Sections 13, 14 and 15, Live Cell Imaging deals channel, wholesalers, merchants, traders, Exploration Discoveries and End, appendix and data source.

Enquire Here Get customization & check discount for report::https://www.marketresearchstore.com/report/global-live-cell-imaging-market-report-2018-industry-366843#InquiryForBuying

Particulars Of The Global Live Cell Imaging Market Research Report

Further part in the report enlists the restraining factors for the Live Cell Imaging market growth. The restraints are explained comprehensively and with details in order that the client can comprehend how these factors are affecting the global Live Cell Imaging market and how such factors can be tackled effectively using suitable measures.

Also, regional study and analysis of global Live Cell Imaging market focused on in the report. Here, the major regions with Live Cell Imaging market establishment have been explained thoroughly. Due to this, our clients will have clarity in understanding the booming markets as well as the potential Live Cell Imaging markets in the near future.

The concluding section relates to the conclusions and observations regarding the global Live Cell Imaging market.

Originally posted here:
Global Live Cell Imaging Market Proceeds To Witness Huge Upswing Over Assessment Period by 2025 - Factory Gate